Contributions
Abstract: EP1421
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: Multiple Sclerosis (MS) impact/progression is traditionally quantified by subjective and objective data including: patient reported outcomes (PRO), reported relapse rate, EDSS and visualized MRI changes. Disability in people with MS (PwMS) can occur by use of delayed/ineffective therapies or other factors. No Evidence of Disease Activity (NEDA) is a treatment desire to maintain ability in PwMS. Use of traditional metrics might be insufficient to provide multidimensional information that is patient centric along a continuum of disability to measure critical milestones of change by current monitoring approaches. Incorporation of both a computerized multidimensional cognitive screening battery (CAB) and analysis of MRI identification of disease impact might provide important information that can impact treatment. The cross-sectional relationship of CAB to digital analysis of brain volume in PwMS has not been established.
Objective: To examine the relationship between digitized brain volume and computerized multi-domain cognitive screening battery in people with MS.
Methods: Retrospective review of PwMS who underwent both a validated multi-domain computerized cognitive screening battery (CAB-NeuroTrax) and MRI digital measurements (Icometrix) of whole brain volume (WBV) and FLAIR white matter (WM) hyper-intensity volume in routine care. CAB-Neurotrax analysis included: memory (Mem), executive function (Exe), attention (Attn), visual spatial (Vis-Spat), verbal function (Ver), and information processing (Inf-Pro), Global Cognitive Summary Score (GCS), as well as the number of Cognitive Domains Impaired #CDI) >1 standard deviation from age/education controls. Linear regression analysis was used to test the significance, which was set at p< 0.05.
Results: 127 PwMS, 72.8% female, average age 51.18 +/- 10.6. Significant relationships were identified: WBV and GCS (p=0.0025), Mem (p=0.0087), Exe (p=0.0107), Verb (p=0.0003), and #CDI (p=0.0059). FLAIR WM Hyper-intensity Volume and GCS (p=0.0034), Mem (p=0.0546), Exe (p=0.0404), Vis-Spat (p=0.0454), Ver (p=0.0045), Inf-Pro (0.0215), and #CDI (p=0.0092).
Conclusion: In PwMS digital measures of brain volume are related to computerized screening assessment of multiple cognitive domains. This quantified objective analytic approach adds examiner independent information about disease impact in a way that can supplement/improve the sensitivity of current approaches to evaluation of disease impact/progression.
Disclosure: (This study was not supported by outside funds):
JK: Nothing to disclose
JS- Nothing to disclose
MZ- Speaker fees (Acorda, Biogen, Genzyme and Teva)
BB- Speaker fees (Biogen, Genotech, Genzyme and Teva).
MB: Nothing to disclose
LF- Nothing to disclose
KB- Nothing to disclose
DG- Nothing to disclose
CS- Nothing to disclose
JW- Nothing to disclose
MG- Research support (Biogen, EMD Serono, Novartis, Sanofi, Teva); speaker fees/consultant (Acorda, Amgen, Biogen, EMD Serono, Medtronic, Novartis, Sanofi, Saol Therapeutics, Teva).
WVH- Employee at Icometrix
Abstract: EP1421
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: Multiple Sclerosis (MS) impact/progression is traditionally quantified by subjective and objective data including: patient reported outcomes (PRO), reported relapse rate, EDSS and visualized MRI changes. Disability in people with MS (PwMS) can occur by use of delayed/ineffective therapies or other factors. No Evidence of Disease Activity (NEDA) is a treatment desire to maintain ability in PwMS. Use of traditional metrics might be insufficient to provide multidimensional information that is patient centric along a continuum of disability to measure critical milestones of change by current monitoring approaches. Incorporation of both a computerized multidimensional cognitive screening battery (CAB) and analysis of MRI identification of disease impact might provide important information that can impact treatment. The cross-sectional relationship of CAB to digital analysis of brain volume in PwMS has not been established.
Objective: To examine the relationship between digitized brain volume and computerized multi-domain cognitive screening battery in people with MS.
Methods: Retrospective review of PwMS who underwent both a validated multi-domain computerized cognitive screening battery (CAB-NeuroTrax) and MRI digital measurements (Icometrix) of whole brain volume (WBV) and FLAIR white matter (WM) hyper-intensity volume in routine care. CAB-Neurotrax analysis included: memory (Mem), executive function (Exe), attention (Attn), visual spatial (Vis-Spat), verbal function (Ver), and information processing (Inf-Pro), Global Cognitive Summary Score (GCS), as well as the number of Cognitive Domains Impaired #CDI) >1 standard deviation from age/education controls. Linear regression analysis was used to test the significance, which was set at p< 0.05.
Results: 127 PwMS, 72.8% female, average age 51.18 +/- 10.6. Significant relationships were identified: WBV and GCS (p=0.0025), Mem (p=0.0087), Exe (p=0.0107), Verb (p=0.0003), and #CDI (p=0.0059). FLAIR WM Hyper-intensity Volume and GCS (p=0.0034), Mem (p=0.0546), Exe (p=0.0404), Vis-Spat (p=0.0454), Ver (p=0.0045), Inf-Pro (0.0215), and #CDI (p=0.0092).
Conclusion: In PwMS digital measures of brain volume are related to computerized screening assessment of multiple cognitive domains. This quantified objective analytic approach adds examiner independent information about disease impact in a way that can supplement/improve the sensitivity of current approaches to evaluation of disease impact/progression.
Disclosure: (This study was not supported by outside funds):
JK: Nothing to disclose
JS- Nothing to disclose
MZ- Speaker fees (Acorda, Biogen, Genzyme and Teva)
BB- Speaker fees (Biogen, Genotech, Genzyme and Teva).
MB: Nothing to disclose
LF- Nothing to disclose
KB- Nothing to disclose
DG- Nothing to disclose
CS- Nothing to disclose
JW- Nothing to disclose
MG- Research support (Biogen, EMD Serono, Novartis, Sanofi, Teva); speaker fees/consultant (Acorda, Amgen, Biogen, EMD Serono, Medtronic, Novartis, Sanofi, Saol Therapeutics, Teva).
WVH- Employee at Icometrix